Latest news and research on all cancers and treatments, updated several times a week
My meeting with the oncologist today was good. The CT scan of my torso that I had a couple of weeks ago was judged to not show any evidence of cancer in any of my organs. Further, none of my organs looked different from how they have looked for years and so I was given the all clear.
We agreed that my high CEA and CA19-9 results are false positives and probably due to my still-healing prostate. They are coming down anyway.
So all’s good for probably a few months at least. The oncologist was happy to sign me off for now, and let me call when I feel there’s something new to discuss.
NSAIDs May Protect Against Cutaneous Squamous Cell Carcinoma
According to the results of a meta-analysis, non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin, may protect against cutaneous squamous cell carcinoma (cSCC). Full details here.
According to the results of a meta-analysis, non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin, may protect against cutaneous squamous cell carcinoma (cSCC). Full details here.
Ibrutinib Shows Activity in Multiple Myeloma
Heavily pretreated multiple myeloma patients are responding to treatment from several inhibitors. See the results of several trials here.
Heavily pretreated multiple myeloma patients are responding to treatment from several inhibitors. See the results of several trials here.
Researchers in Israel have taken a truly innovative approach toward treating cancer in their attempt to harness the body's own immune system to fight ...
Nivolumab is the latest in a new generation of cancer therapies that unleash the immune system to destroy cancer cells. This approach, which MSK ...
... immune system disease (like advanced HIV), being on medications that suppress the immune system, or having recently had cancer chemotherapy.
... foreign or toxic substances that trigger production of an antibody by the immune system — are added. ... That could stop the cancer from returning.
"GEN-1 is designed to locally activate IL-12 production which can stimulate the patient's immune system to attack and destroy cancer," stated Dr.
Physician use of perioperative chemotherapy (POC) for muscle-invasive bladder cancer (MIBC) increased by 35% from 2006 to 2010, following the ...
These genetic alterations are implicated in the pathogenesis and progression of DLBCL, FL, as well as bladder cancer and other solid tumor types.
Transitional Cell Cancer (Urothelial Cell Cancer) – Pipeline Review, H2 2014′, provides an overview of the Transitional Cell Cancer (Urothelial Cell ...
"Developing more effective immunotherapy approaches to ovarian cancer is a high priority for those of us who care for the thousands of patients ...
Metastatic melanoma is the deadliest form of skin cancer, and until recently ... “This type of dramatic benefit is not typically seen in cancer patients. ... The first such immunotherapy drug, ipilimumab, was approved in 2011 and acts on ...
ACOG Recommends Salpingectomy for Ovarian Cancer Prevention
ACOG recently released a Committee Opinion on the use of salpingectomy for ovarian cancer prevention in at-risk women undergoing routine pelvic surgery.
ACOG recently released a Committee Opinion on the use of salpingectomy for ovarian cancer prevention in at-risk women undergoing routine pelvic surgery.
Oral Contraceptives May Reduce BRCA-Associated Ovarian Cancer Risk
Researchers have identified several factors, including breastfeeding and oral contraceptives, that may decrease the risk of BRCA-associated ovarian cancer.
Researchers have identified several factors, including breastfeeding and oral contraceptives, that may decrease the risk of BRCA-associated ovarian cancer.
FDA Approves Second PD-1 Inhibitor, Nivolumab, for Melanoma
The FDA has granted nivolumab (Opdivo) accelerated approval for the treatment of patients with unresectable or metastatic melanoma who no longer respond to other treatments.
The FDA has granted nivolumab (Opdivo) accelerated approval for the treatment of patients with unresectable or metastatic melanoma who no longer respond to other treatments.
New Drugs Could Treat BRAF-Inhibitor Resistant Melanoma
Researchers have identified two new panRAF inhibitors that could be used to treat patients with BRAF- or NRAS-mutant melanoma, and those who have developed resistance to BRAF inhibitors.
Researchers have identified two new panRAF inhibitors that could be used to treat patients with BRAF- or NRAS-mutant melanoma, and those who have developed resistance to BRAF inhibitors.
T-DM1 Trial Disappoints in HER2-Positive Breast Cancer
Results of the MARIANNE trial found that HER2-positive breast cancer patients treated with T-DM1 had similar survival to those on the current standard of care.
Results of the MARIANNE trial found that HER2-positive breast cancer patients treated with T-DM1 had similar survival to those on the current standard of care.
Bisphosphonates May Cut Risk of Endometrial Cancer
An analysis of a large number of women suggested that those who use bisphosphonates, a bone medication used to treat osteoporosis and other bone loss diseases, have a reduced risk of endometrial cancer.
An analysis of a large number of women suggested that those who use bisphosphonates, a bone medication used to treat osteoporosis and other bone loss diseases, have a reduced risk of endometrial cancer.
Longer Androgen Suppression Not Better for Intermediate-Risk Prostate Cancer
Extending the duration of androgen suppression in men with intermediate-risk prostate cancer prior to radiotherapy led to more adverse events and did not improve outcomes.
Extending the duration of androgen suppression in men with intermediate-risk prostate cancer prior to radiotherapy led to more adverse events and did not improve outcomes.
PIK3CA Mutations Matter in HER2-Positive Breast Cancer
Two recently published studies suggest that PIK3CA mutations cannot be used as a predictive biomarker to guide therapy in HER2-positive breast cancer.
Two recently published studies suggest that PIK3CA mutations cannot be used as a predictive biomarker to guide therapy in HER2-positive breast cancer.
Clonal Hematopoiesis May Raise Risk of Blood Cancers
Clonal hematopoiesis with somatic mutations is strongly associated with the risk of developing blood cancers, according to a new study.
Clonal hematopoiesis with somatic mutations is strongly associated with the risk of developing blood cancers, according to a new study.
Febrile Neutropenia Costly Problem in Metastatic Cancer
Risk for febrile neutropenia was high among patients with metastases from a variety of common cancers and was associated with numerous clinical and economic consequences, including increased morbidity and mortality.
Risk for febrile neutropenia was high among patients with metastases from a variety of common cancers and was associated with numerous clinical and economic consequences, including increased morbidity and mortality.
MEK/BRAF Inhibitor Combo Reduces Death by One-Third in Melanoma
Patients with untreated metastatic melanoma had a significant improvement in overall survival when treated with a BRAF/MEK inhibitor combo.
Patients with untreated metastatic melanoma had a significant improvement in overall survival when treated with a BRAF/MEK inhibitor combo.
Recently Approved ALL Drug Gets Big Price Tag
According to a report, two courses of the newly approved agent blinatumomab, for relapsed or refractory B-cell precursor ALL, will cost a staggering $178,000.
According to a report, two courses of the newly approved agent blinatumomab, for relapsed or refractory B-cell precursor ALL, will cost a staggering $178,000.
MRI Improves Breast Cancer Screening in Older BRCA Carriers
Adding an MRI to a mammogram improved the sensitivity of breast cancer screening in women 50 years of age or older who are BRCA mutation carriers.
Adding an MRI to a mammogram improved the sensitivity of breast cancer screening in women 50 years of age or older who are BRCA mutation carriers.
Right Age for Lynch Syndrome Screening Still in Question
The results of a recent meta-analysis suggest that carriers of the MLH1 or MSH2 mutations associated with Lynch syndrome could delay regular colonoscopies until age 30.
The results of a recent meta-analysis suggest that carriers of the MLH1 or MSH2 mutations associated with Lynch syndrome could delay regular colonoscopies until age 30.
Sharp Rise in Mastectomy in Early-Stage Breast Cancer
A retrospective cohort study of women treated for early-stage breast cancer has confirmed rising trends in the proportion of patients who undergo mastectomy.
A retrospective cohort study of women treated for early-stage breast cancer has confirmed rising trends in the proportion of patients who undergo mastectomy.
Cancer News in Science Daily
'Seeing' hydrogen atoms to unveil enzyme catalysis that may play key role in cancer drug development
Scientists have used a new instrument to map an enzyme that could play an important role in anti-cancer drug development.
By looking at the expression levels of downstream genes of the regulators in breast cancer, researchers have identified a gene signature in E2F4 that is predictive of estrogen receptor positive (ER+) breast cancer. The findings define a new opportunity for personalizing medicine for women whose Oncotype DX assay results classify them as of 'intermediate-risk for recurrence.'
Following cancer prevention guidelines from the American Cancer Society may modestly reduce your overall risk of developing cancer and have a greater impact on reducing your overall risk of dying early, a study of nearly a half-million Americans has found. Having a healthy body weight and staying active appeared to have the most positive impact.
A patient-centred approach to assessing the side effects of radiotherapy has been proposed by researchers. Their study results have shown that it may be able to improve the detection and management of treatment-related toxicity.
Dopamine -- an inexpensive drug currently used to treat heart, vascular and kidney disorders -- can be safely used in cancer treatment to curb the growth of blood vessels in tumors, a new study shows.
Scientists have synthesized marine alkaloids with anti-cancer and therapeutic properties through a sequential C-H functionalization strategy.
Tambahkan Komentar